LIQUIDIA CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LIQUIDIA CORPORATION (LQDA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $10.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $10.37M, a 49.64% increase year-over-year.
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $9.22M, a 23.92% increase year-over-year.
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.90M, a 61.81% increase year-over-year.
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.93M, a 58.51% increase year-over-year.
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $29.47M, a 56.72% increase from fiscal 2024.
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $18.81M, a 86.40% increase from fiscal 2023.
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $10.09M, a 8.51% increase from fiscal 2022.
- LIQUIDIA CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $9.30M, a 37.83% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10.37M 10-Q · filed 2026-08-12 | $19.59M derived: sum of 2 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $9.22M 10-Q · filed 2026-08-12 | |||||
| 2025-12-31 | $29.47M 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | $7.90M 10-Q · filed 2025-11-03 | $14.83M derived: sum of 2 quarters · filed 2026-08-12 | $22.27M derived: sum of 3 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $6.93M 10-Q · filed 2026-08-12 | $14.37M derived: sum of 2 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $7.44M 10-Q · filed 2026-08-12 | |||||
| 2024-12-31 | $18.81M 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | $4.88M 10-Q · filed 2025-11-03 | $9.25M derived: sum of 2 quarters · filed 2025-11-03 | $13.78M derived: sum of 3 quarters · filed 2025-11-03 | |||
| 2024-06-30 | $4.37M 10-Q · filed 2025-11-03 | $8.90M derived: sum of 2 quarters · filed 2025-11-03 | ||||
| 2024-03-31 | $4.52M 10-Q · filed 2025-11-03 | |||||
| 2023-12-31 | $10.09M 10-K · filed 2026-03-05 | |||||
| 2023-09-30 | $2.49M 10-Q · filed 2024-11-13 | $4.99M derived: sum of 2 quarters · filed 2024-11-13 | $7.54M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $2.50M 10-Q · filed 2024-11-13 | $5.05M derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $2.55M 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | $9.30M 10-K · filed 2024-03-13 | |||||
| 2022-09-30 | $1.65M 10-Q · filed 2023-11-07 | $3.35M derived: sum of 2 quarters · filed 2023-11-07 | $7.48M derived: sum of 3 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $1.70M 10-Q · filed 2023-11-07 | $5.83M derived: sum of 2 quarters · filed 2023-11-07 | ||||
| 2022-03-31 | $4.13M 10-Q · filed 2023-11-07 | |||||
| 2021-12-31 | $6.75M 10-K · filed 2023-03-20 | $6.75M 10-K · filed 2022-03-17 | ||||
| 2021-09-30 | $1.22M 10-Q · filed 2022-11-08 | $1.22M 10-Q · filed 2021-11-03 | $2.18M derived: sum of 2 quarters · filed 2022-11-08 | $2.92M derived: sum of 3 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $953.00K 10-Q · filed 2022-11-08 | $953.22K 10-Q · filed 2021-08-10 | $1.70M derived: sum of 2 quarters · filed 2022-11-08 | |||
| 2021-03-31 | $745.00K 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $3.95M 10-K · filed 2022-03-17 | |||||
| 2020-09-30 | $1.08M 10-Q · filed 2021-11-03 | $2.07M derived: sum of 2 quarters · filed 2021-11-03 | $2.95M derived: sum of 3 quarters · filed 2021-11-03 | |||
| 2020-06-30 | $988.12K 10-Q · filed 2021-11-03 | $1.87M derived: sum of 2 quarters · filed 2021-11-03 | ||||
| 2020-03-31 | $878.96K 10-Q · filed 2021-11-03 | |||||
| 2019-12-31 | $3.38M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |